Creative Medical Technology Holdings Achieves Major Clinical Milestone with Positive ADAPT Trial Data and Demonstrates Promising Safety Profile for CELZ-201 (Olastrocel) in Chronic Lower Back Pain Treatment.

Creative Medical Technology Holdings announced positive interim data from its ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain. The study showed statistically significant improvements in functional disability and pain, confirming a favorable safety profile. This marks a major inflection point for the company, transitioning CELZ-201 from a clinical program to a strategic asset with significant potential value for patients and shareholders.